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ABSTRACT 
 
Alkylating agents comprise a major class of front-line cancer chemotherapeutic 
compounds, and while these agents effectively kill tumor cells, they also damage healthy 
tissues.  Although base excision repair (BER) is essential in repairing DNA alkylation 
damage, under certain conditions, initiation of BER can be detrimental.  Here we 
illustrate that the alkyladenine DNA glycosylase (AAG) mediates alkylation-induced 
tissue damage and whole-animal lethality following exposure to alkylating agents.  Aag-
dependent tissue damage, as observed in cerebellar granule cells, splenocytes, 
thymocytes, bone marrow cells, pancreatic -cells, and retinal photoreceptor cells was 
detected in wildtype mice, exacerbated in Aag transgenic mice, and completely 
suppressed in Aag
-/-
 mice.  Additional genetic experiments dissected the effects of 
modulating both BER and Parp1 on alkylation sensitivity in mice and determined that 
Aag acts upstream of Parp1 in alkylation-induced tissue damage; in fact cytotoxicity in 
WT and Aag transgenic mice was abrogated in the absence of Parp1.  These results 
provide in vivo evidence that Aag-initiated BER may play a critical role in determining 
the side-effects of alkylating agent chemotherapies, and that Parp1 plays a crucial role in 
Aag-mediated tissue damage.  
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AUTHOR SUMMARY 
Alkylating agents are genotoxic chemicals that induce both toxic and mutagenic DNA 
damage through addition of an alkyl group to DNA.  Alkylating agents are routinely and 
successfully used as chemotherapeutic therapies for cancer patients, with one major 
disadvantage being the significant toxicity induced in non-tumor tissues.  Accordingly, 
identifying factors that modify susceptibility to alkylation-induced toxicity will provide 
valuable information in designing cancer therapeutic regimens.  This study used mouse 
genetic experiments to investigate whether proteins important in the base excision repair 
pathway modulate susceptibility to alkylating agents.  In addition to whole-animal 
toxicity at high doses, treatment of mice with alkylating agents resulted in severe damage 
to numerous tissues including the cerebellum, retina, bone marrow, spleen, thymus, and 
the pancreas.  We illustrate that the DNA glycosylase, Aag, can actually confer, rather 
than prevent, alkylation sensitivity at both the whole-animal and tissue level; i.e., Aag 
transgenic animals are more susceptible than wild type, whereas Aag-deficient animals 
are less susceptible than wild type to alkylation-induced toxicity.  Further genetic 
experiments show that the Aag-mediated alkylation sensitivity is dependent on Parp1.  
Given that we observe a wide range of human AAG expression among healthy 
individuals, this and other base excision repair proteins may be important factors 
modulating alkylation susceptibility. 
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INTRODUCTION 
DNA damage continually arises from environmental agents and reactive byproducts of 
normal cellular function.  Moreover, DNA damage is deliberately induced during the 
course of cancer chemotherapy.  Such damage can result in cell death, mutagenesis, and 
genetic instability thus promoting tissue degeneration, aging, cancer, and sometimes 
death.  DNA repair pathways have evolved to cope with recurring DNA damage, 
providing protection against carcinogenesis, neurodegeneration, and premature aging 
[1,2,3,4,5].  Understandably, loss of function mutations have been extensively studied, 
whereas genetic variants that result in increased DNA repair activity have not received 
the same attention, primarily because decreased DNA repair is thought to be more 
relevant for increased cancer risk.  While this concept is accurate for many DNA repair 
proteins [1,2,3], a growing body of evidence suggests that increased levels of certain 
DNA repair enzymes can result in loss of coordination between the enzymatic steps 
within a particular DNA repair pathway; such loss of coordination can negatively impact 
cellular homeostasis [6,7,8]. 
 
The base excision repair (BER) pathway acts on a wide range of DNA base lesions 
including alkylated, oxidized, and deaminated bases, as well as abasic (AP) sites and 
DNA single-strand breaks (SSBs) (reviewed in [6,9]).  In its most simplified form, BER 
is coordinated into 4 main steps (Figure 1A).   DNA glycosylases recognize and excise 
specific base lesions by cleaving the N-glycosyl bond, forming an AP site.  AP 
endonuclease (APE1) then hydrolyzes the phosphodiester backbone, generating a single-
stranded DNA break (SSB) with 3'OH and 5'deoxyribose-5-phosphate (5'dRP) termini.  
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DNA polymerase  (Pol ) contains a lyase domain that removes the 5'dRP terminus and 
a polymerase domain that replaces the missing nucleotide.  Finally, BER is completed 
upon ligation of the nick by DNA Ligase I or the Xrcc1/Ligase III complex (Figure 
1A).   
 
Importantly, numerous BER intermediates (AP sites, 5'dRP termini, and SSBs) are toxic 
if allowed to accumulate rather than being efficiently shuttled through the downstream 
BER steps (Figure 1A).  Both SSBs and AP sites exert their toxicity as a function of 
blocking transcription and replication [10].  Further, large numbers of SSBs can 
indirectly induce toxicity through the hyperactivation of poly(ADP-ribose) polymerase 1 
(Parp1) [11] (Figure 1B).  AP sites can also be mutagenic; although translesion DNA 
polymerases can prevent toxicity by bypassing AP sites, such bypass can generate point 
mutations [12,13,14,15,16].  The 5'dRP intermediate is particularly toxic in mouse 
embryonic fibroblasts (MEFs) and the alkylation sensitivity of Pol deficient MEFs is 
almost completely suppressed upon expression of the Pol 5'dRP lyase domain [17].  The 
toxic nature of BER intermediates underscores why this pathway must be tightly 
regulated and why alterations in any step of the pathway, without compensatory changes 
in upstream/downstream steps, can result in the accumulation of toxic intermediates.  A 
clear example of this was illustrated by the fact that hypersensitivity to the alkylating 
agent methyl methanesulfonate (MMS) in Pol-/- MEFs is completely suppressed if BER 
is not initiated by the alkyladenine DNA glycosylase (AAG, also known as MPG, 
ANPG) [18].  Therefore, although BER is essential for the repair of many different types 
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of DNA damage, it must be carefully regulated to avoid the accumulation of toxic BER 
intermediates. 
 
Aag has a wide substrate specificity, excising numerous structurally-diverse lesions, 
some of which are innocuous (e.g. 7meG), while others can be replication-blocking and 
cytotoxic (e.g. 3meA) [19,20,21,22,23,24,25,26] .  The absence of Aag should therefore 
result in unrepaired alkylated DNA bases that are replication-blocking lesions, thus 
increasing cytotoxicity; strikingly, the converse is seen in certain Aag deficient tissues.  
Aag
-/-
 bone marrow cells are MMS resistant in ex vivo survival assays [27], and Aag
-/-
 
retinal photoreceptor cells are remarkably refractory to MMS-induced death [28].  Thus, 
when BER is not initiated, MMS-induced cytotoxicity is avoided, presumably by 
preventing the accumulation of toxic intermediates, and by translesion DNA synthesis 
(TLS) bypassing lesions in replicating cells (Figure 1B).     
 
The multi-functional protein, Parp1, mediates several cellular processes including stress 
responses, transcriptional regulation, and DNA SSB repair and BER [29,30,31].  Parp1’s 
role as a molecular sensor of SSBs is well established; upon binding DNA breaks, Parp1 
adds poly(ADP-ribose) (PAR) polymers to numerous nuclear proteins including itself, 
DNA polymerases, DNA ligases, transcription factors, and histones [30,32].  Parp1 
automodification facilitates BER by recruiting the scaffold protein XRCC1 that in turn 
facilitates the formation of a BER repair complex comprising APE1, DNA Pol, and 
DNA ligase III [33,34,35].  Further, PARylation of histones, Parp1, and chromatin 
remodeling enzymes relaxes chromatin allowing DNA repair proteins access to damaged 
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DNA [36,37,38].  Importantly, Parp1 is also a cell death mediator [11]; upon excessive 
levels of DNA damage, Parp1 hyperactivation vastly increases NAD
+
 consumption 
resulting in depletion of both NAD
+
 and ATP, such that cells succumb to bioenergetic 
failure (Figure 1B).  Independent of NAD
+
/ATP depletion, the PAR polymer can 
stimulate cell death by facilitating translocation of apoptosis inducing factor (AIF) from 
mitochondria to the nucleus, resulting in chromatin condensation, caspase-independent 
DNA degradation, and ultimately cell death [11,39,40]. While the various roles of Parp1 
in programmed necrosis are still being elucidated, it is quite clear that Parp1 is a central 
player.   
 
Imbalanced BER can arise either by increased DNA glycosylase activity, or by a decrease 
in any downstream BER step (reviewed in [6]).  For example, decreased Pol activity, as 
observed in the PolY265C/Y265C knock-in mice, results in accumulated BER intermediates, 
causing severe physiological consequences [41].  Interestingly, recent studies generated 
imbalanced BER by both increasing Aag activity and eliminating Pol activity; such cells 
displayed enhanced alkylation sensitivity [42,43].  Although BER imbalance increases 
alkylation sensitivity in cultured cells, the effects of BER imbalance on in vivo alkylation 
sensitivity have not yet been extensively studied.  Using transgenic mice exhibiting 
modestly increased Aag activity, we investigated the effects of imbalanced BER in many 
tissues.  We show that AagTg mice exhibit dramatic alkylation sensitivity, at both the 
tissue and the whole-body level, consistent with imbalanced BER leading to the 
accumulation of toxic intermediates.  Moreover, we show that Parp1 deficiency prevents 
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alkylation-induced damage in numerous tissues, indicating that the Aag-dependent 
alkylation sensitivity observed in vivo occurs in a Parp1-dependent manner.   
 9 
RESULTS 
Generation of AagTg mice to model BER imbalance in vivo 
BER modulation has recently attracted attention as a way to potentiate alkylation 
sensitivity [6,29,43,44,45,46,47].  To investigate the consequences of imbalanced BER in 
vivo, we generated Aag transgenic (AagTg) mice; Supplemental Table 1 displays the Aag 
activity levels in three transgenic founder (Fo) lines.  Fo line 243 exhibits increased Aag 
activity in all tissues examined, with a ~2-9-fold increase compared to WT levels 
(Supplemental Table 1 and Supplemental Figure 1A).   Fo line 8756 displays negligible 
increases in Aag activity in every tissue except the cerebellum.  Finally, Aag activity in 
Fo line 943 tissues falls in-between, with 1.5-4-fold increases compared to WT levels.  
To add context to the range of Aag activities in our AagTg mice, we examined human 
AAG activity in peripheral blood mononuclear cells (PBMC) of healthy individuals.  We 
observe >10-fold variation in AAG activity in this healthy population, as measured by 
excision of 1N6 ethenoadenine (A) bases from DNA (Figure 2); A represents one of 
AAG’s many substrates [22,25].  This wide range of AAG activity among healthy 
individuals is similar to that recently reported [7].   
  
Imbalanced BER increases whole-body sensitivity to alkylating agents. 
AagTg mice are viable and fertile, and an aging study revealed no apparent differences in 
lifespan or tumor incidence between WT, Aag
-/- 
and AagTg Fo line 243 (Supplemental 
Figure 1B and data not shown).  Although increased Aag activity in vivo does not 
significantly alter longevity or spontaneous tumor incidence, it does profoundly affect 
how mice respond to DNA damage.  Similar to our previous published findings, WT and 
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Aag
-/-
 mice display the same approximate LD50 for MMS (150mg/kg) (Table 1) [27].  
However, AagTg Fo 243, with a 2-9-fold increase in Aag activity, exhibits a dramatic 
increase in MMS sensitivity (Table 1).  Mice with intermediate Aag levels (AagTg Fo 
943) have an intermediate LD50, and AagTg Fo 8756, with negligible Aag activity in most 
tissues, exhibits the same MMS LD50 as WT and Aag
-/-
 mice (Table 1).  Therefore, 
increased Aag activity sensitizes animals to MMS-induced whole-body lethality.   
 
We next determined whether Aag activity affects the LD50 for other genotoxic agents: N-
methyl-N-nitrosourea (MNU), azoxymethane (AOM), mitomycin C (MMC), and 
chloroacetaldehyde (CAA).  Table 2 illustrates that while the AagTg Fo 243 mice show 
dramatically increased whole-body sensitivity to three different methylating agents 
(MMS, MNU and AOM), they were not sensitized to non-methylating genotoxic agents 
(MMC and CAA).   Thus, Aag activity dictates sensitivity to both SN1 (MNU and AOM) 
and SN2 methylating agents (MMS), but not to the other genotoxic agents examined.  
Since the increased Aag activity in AagTg Fo 243 mice falls within the range observed in 
PBMCs of a healthy human population, this founder line was chosen to further examine 
the consequences of BER imbalance, and are henceforth referred to as AagTg mice.  
 
AagTg mice exhibit increased MMS cytotoxicity in numerous, but not all tissues  
Histopathological analysis was performed on tissues harvested from WT, Aag
-/-
, and 
AagTg mice 24h following MMS treatment (150 mg/kg).  Because massive cell death 
was observed in rapidly-proliferating tissues including the spleen, thymus, and bone 
marrow (BM) for all genotypes, we reduced the MMS dose to 75 mg/kg to better discern 
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any differences in sensitivity in these tissues.   Even with the reduced MMS dose, AagTg 
mice displayed evidence of whole-body toxicity whereas WT and Aag
-/-
 mice did not.  
Remarkably, as early as 24h following MMS treatment, AagTg mice exhibit greater 
reductions in body weight than WT or Aag
-/-
 mice (Figure 3A), losing >10% of their BW 
by 24h; the decreased body weight remains significantly greater than that for WT and 
Aag
-/-
 mice for over 3 weeks (Figure 3B).  Moreover, 24h following MMS treatment (75 
mg/kg), we observe gross tissue atrophy in the thymus and spleen in AagTg mice; AagTg 
mice exhibit 46% and 53% decreases in thymus and spleen weight, respectively, 
compared to untreated tissues (Figure 3C).   WT mice also exhibit a slight (26%) but 
significant decrease in spleen weight following MMS treatment but no evidence of 
thymic atrophy (compared to untreated mice).  Strikingly, Aag
-/-
 mice are completely 
protected from the MMS-induced atrophy in both the thymus and spleen (Figure 3C).  
Further, ex vivo clonogenic survival assays illustrate that AagTg BM cells display 
dramatically increased MMS sensitivity, compared to WT and Aag
-/-
 mice; as previously 
published, Aag
-/-
 BM cells are less sensitive than WT BM cells to MMS (Figure 3D) [27].  
However, not all tissues that exhibit increased Aag activity reveal evidence of gross 
tissue atrophy.  Supplemental Figure 2 illustrates that tissue weights of the heart, kidney, 
brain, gonadal fat pad, skeletal muscle and liver remain unchanged following MMS 
treatment (75 mg/kg).  Finally, Supplemental Figure 3 illustrates that AagTg mice exhibit 
severe cell death within the pancreatic -islets following MMS treatment (150 mg/kg), 
which is not observed in WT or Aag
-/-
 mice.  The -cells exhibit nuclear fragmentation 
and pyknosis, a state of increased chromatin condensation.  Taken together, these results 
reveal that the ~2-9 fold increase in Aag activity in the thymus, spleen, BM, and pancreas 
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relative to WT (Supplemental Table 1) renders these tissues dramatically more sensitive 
to the toxic effects of MMS.  Further, we observe increased MMS toxicity in only a 
subset of tissues expressing the Aag transgene, underscoring the importance of cellular 
context in determining MMS sensitivity in AagTg mice. 
 
Unexpectedly, 24h following a high MMS dose (150 mg/kg), we observe cell death in the 
cerebellar granule cells, which comprise 99% of the granular layer of the cerebellum.  
Following MMS treatment, there is a drastic change in cerebellar morphology in this 
region in AagTg mice.  We observe severe cerebellar lesions containing numerous 
pyknotic nuclei surrounded by white spaces, indicative of edema (Figure 4A).  Pyknotic 
nuclei, but not edema, are also observed, albeit at a lower frequency, in the cerebella of 
treated WT mice, whereas the cerebella of treated Aag
-/-
 mice are indistinguishable from 
untreated mice (Figure 4A).  The regions of edema were quantitated using image analysis 
software; examples of colorized lesions are shown in the lowest panel of Figure 4A.  In 
untreated mice, no edema is observed (Figure 4B).  However, 24h following MMS (150 
mg/kg), there is an obvious increase in edema in AagTg mice compared to either WT or 
Aag
-/-
 mice, and a trend towards an increase in WT compared to Aag
-/-
 mice (p=0.308), 
suggesting that Aag
-/-
 mice are protected against MMS-mediated cerebellar toxicity.  
Here we illustrate that MMS treatment results in severe cerebellar damage that is Aag-
dependent.  Although cerebellar damage has been described following treatment of early 
postnatal mice (PND3) with the alkylating agents methylazoxymethanol and 
mechlorethamine, to our knowledge, it has not previously been demonstrated following 
treatment of adult mice [48,49].  
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Aag-dependent, MMS-induced cerebellar degeneration results in impaired motor 
function  
Given the importance of the cerebellum in coordinating motor function, we investigated 
whether MMS-induced cerebellar lesions result in diminished motor control.  Decreased 
mobility was observed in all genotypes following a high MMS dose (150 mg/kg) (data 
not shown), so we reduced the MMS dose (90 mg/kg) for gait comparisons between WT, 
Aag
-/-
, and AagTg mice.  The gait of all genotypes was indistinguishable under untreated 
conditions (Supplemental Figure 4).  However, three hours following MMS treatment, 
the gait of WT and Aag
-/-
 mice is unchanged whereas AagTg mice exhibit severe gait 
abnormalities including immobility, circling, and walking backwards (Figure 5A).  We 
quantitated motor defects by performing an accelerating speed rotarod test.  To ensure all 
genotypes were capable of performing for >30 seconds on the rotarod test, we further 
reduced the MMS dose (60 mg/kg).  Without MMS exposure, all genotypes performed 
comparably (Figure 5B).   However, three hours following MMS treatment, we observed 
a dramatic decrease in rotarod performance for AagTg mice compared to WT and Aag
-/-
 
mice (Figure 5B).  Although the AagTg mice slightly improved their performance by 4 
hours, it remained significantly decreased compared to WT and Aag
-/-
 mice (Figure 5B).  
Treated WT and Aag
-/-
 mice performed similarly to untreated mice, indicating that MMS 
at this dose (60 mg/kg) caused no motor dysfunction in WT or Aag
-/-
 mice.    
 
We next increased the MMS dose to one that resulted in obviously impaired motor 
function in WT mice (140 mg/kg), and again examined motor function using the rotarod 
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test (Figure 5C); the AagTg mice could not be included in this experiment due to their 
extreme sensitivity at this MMS dose.  Strikingly, even at this high dose, Aag
-/- 
mice
 
remain completely protected against MMS-induced motor dysfunction; they not only 
exhibit significantly better performance than WT mice, but their performance following 
MMS remains the same as in untreated conditions (Figure 5C).  This observation is 
consistent with the absence of histological cerebellar lesions in Aag
-/- 
mice following 
MMS (150 mg/kg) treatment (Figure 4A).  Together, these data underscore the 
importance of BER coordination in neuronal homeostasis; MMS induces cerebellar 
degeneration that is exacerbated by imbalanced BER in AagTg mice.  Perhaps most 
importantly, the elimination of BER initiation in Aag
-/- 
mice
 
completely suppresses 
MMS-induced cerebellar toxicity. 
 
The absence of Parp1 suppresses Aag-dependent MMS-induced toxicity in several 
tissues 
Given the role for Parp1 in mediating alkylation toxicity, we next set out to determine 
whether eliminating Parp1 could modulate the MMS-induced cytotoxicity observed in 
WT and AagTg mice; to explore this possibility, we utilized Parp1
-/- 
mice [50].  We first 
investigated MMS-induced retinal degeneration (RD).  As previously illustrated, MMS 
induces the selective degeneration of the photoreceptors in the retinal outer nuclear layer 
(ONL) in WT mice, whereas juxtaposed retinal layers are unaffected [28].  While Aag
-/- 
mice are completely protected from such RD, AagTg mice are hypersensitive compared 
to WT and Aag
-/- 
mice, as observed by decreased number of cells found within the ONL 
(Figure 6 and [28]).  Strikingly, we observe that Parp1
-/- 
mice are also completely 
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protected against MMS-induced RD (Figure 6).  Moreover, MMS-induced RD is 
completely abrogated in AagTg/Parp1
-/- 
mice, indicating that Parp1 deficiency 
completely suppresses the Aag-dependent MMS-hypersensitivity in photoreceptors of 
AagTg mice (Figure 6).  To confirm that Parp1 enzymatic activity is stimulated during 
MMS-induced Aag-dependent RD, we evaluated Parp1 activation by immunodetection of 
the PAR polymer.  Supplemental Figure 5 shows that increased PAR polymer staining is 
observed 24h following MMS treatment, in an Aag-dependent manner, confirming that 
MMS-induced RD is preceded by Parp1 activation.  Similarly, we observe that Parp1 
deficiency is able to suppress the pancreatic -cell death observed in AagTg mice 
following an acute MMS treatment (Supplemental Figure 6).  Together, these data 
indicate that the BER intermediates exert their toxicity through the hyperactivation of 
Parp1.  Further, we find that deletion of Parp1 prevents MMS-induced toxicity and that 
both Aag and Parp1 are required for MMS-induced cell death.  
 
We next investigated the requirement for Parp1 in MMS-induced cerebellar degeneration.  
While MMS (150 mg/kg) induces severe cerebellar lesions in AagTg mice (Figure 4A), 
Parp1 deficiency completely suppresses this Aag-dependent, alkylation-induced 
cerebellar toxicity (Figure 7A).  Image analysis confirms that the drastic increase in the 
area of edema in MMS-treated AagTg mice was completely abrogated in AagTg/Parp1
-/-
 
mice (Figure 7B).  Consistent with rescue of cerebellar lesions in AagTg/Parp1
-/-
 mice 
(Figure 7B), we illustrate using gait analysis that Parp1 deficiency prevents the motor 
dysfunction observed following MMS treatment in AagTg mice (Supplemental Figure 7).  
Additionally, rotarod assays were performed in WT, AagTg and AagTg/Parp
-/- 
mice to 
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quantitate motor function.  Following MMS (60 mg/kg), the motor function in WT mice 
remain unaffected, whereas AagTg mice exhibit significantly diminished performance 
(Figure 7C).  Importantly, following MMS, AagTg/Parp1
-/-
 mice perform just as well as 
WT mice, indicating that the Aag-dependent MMS-hypersensitivity in the cerebella of 
AagTg mice is completely dependent on Parp1 (Figure 7C).  Further, the Parp1 
deficiency was sufficient to prevent the motor dysfunction observed at high MMS doses.  
As described above, at high MMS (140mg/kg), WT mice exhibit severe motor 
dysfunction (Figures 5C and 7D); however we find that like Aag
-/-
 mice, Parp1
-/-
 mice are 
protected against MMS-induced motor dysfunction and exhibit enhanced rotarod 
performance compared to MMS-treated WT mice (Figure 7D).  The mice in this 
experiment are on a mixed C57Bl/6:129S6 background, and the slight decrease in rotarod 
performance observed here, compared to Figure 5, can be attributed to differences in 
genetic background, as previously shown [51,52].  Together, these data (Figure 6, 7, and 
Supplemental Figure 6) indicate that both Aag and Parp1 are required for the severe 
MMS-mediated cytotoxicity observed in retinal photoreceptors, pancreatic -cells, and 
cerebellar granule cells.      
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DISCUSSION 
Using AagTg mice, we have investigated the in vivo consequences of imbalanced BER.  
Although increased human AAG activity was recently linked to elevated lung cancer risk 
[7] and decreased survival of glioma patients [53], increased Aag activity in mice does 
not affect spontaneous tumorigenesis or overall longevity.  However, dramatic in vivo 
consequences of imbalanced BER were revealed upon treating AagTg mice with 
alkylating agents.  AagTg mice exhibited increased whole-animal lethality to both SN1 
and SN2 methylating agents, but not to other genotoxic agents.  Our data suggest that 
under basal conditions, the level of BER intermediates produced during the repair of 
spontaneous DNA damage is readily accommodated by the downstream BER enzymes.  
However, in the presence of higher levels of DNA base damage generated by alkylating 
agents, Aag initiates BER at a rate such that downstream BER enzymes are unable to 
efficiently process the toxic BER intermediates, resulting in cell death and tissue damage, 
and potentially in the death of the animal (Figure 1).  Therefore, it may be predicted that 
patients exhibiting increased AAG activity may exhibit increased sensitivity or more 
detrimental side-effects to alkylating chemotherapeutic agents.  Indeed, AAG expression 
does predict temozolomide sensitivity in glioblastoma and ovarian cancer cell lines 
[47,54], and AAG expression inversely correlates with survival of glioma patients 
following treatment [53].  Together, the data presented here as well as published findings 
provide justification for an epidemiological study examining alkylation sensitivity in 
correlation with AAG activity levels.   
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Imbalanced BER in AagTg mice confers increased MMS sensitivity to cells in the 
thymus, spleen, bone marrow, retina, pancreas, and cerebellum.  Further, Aag activity 
predicts MMS toxicity in vivo, such that relative sensitivities are as follows:  AagTg > 
WT > Aag
-/-
.  However, Aag activity is not the sole determinant of MMS-mediated tissue 
cytotoxicity; numerous tissues in the AagTg mice exhibit ~5-8 fold increases in Aag 
activity (e.g. heart, kidney, liver) but show no evidence of increased MMS sensitivity 
(Supplemental Figure 2), underscoring the importance of cellular context in determining 
Aag-mediated alkylation sensitivity.  It remains to be determined why only a subset of 
cell types are susceptible to Aag-mediated alkylation toxicity.  In the highly-proliferative 
thymus, spleen, and bone marrow, unrepaired BER intermediates presumably result in 
replication fork collapse and DSBs, thus triggering cell death.  However, pancreatic -
cells are not highly-proliferative and both the adult cerebellar granule cells and retinal 
photoreceptor cells are non-replicating, post-mitotic tissues [55], indicating cell death 
must be replication-independent.  It is important to note that even within tissues 
exhibiting MMS sensitivity, toxicity is not uniform across all cell types in the tissue.  For 
example, only the ONL of the retina undergoes MMS-induced degeneration whereas the 
juxtaposed retinal layers remain intact.  Similarly, following MMS treatment, cerebellar 
purkinje cells remain unaffected while neighboring cerebellar granule cells are ablated.  
Why are some cells so sensitive, whereas others are resistant?  The activity of 
downstream BER proteins in the sensitive cells may simply be insufficient to process 
accumulating BER intermediates; this and other possibilities are currently under 
investigation.  Together, our data emphasize the concept that BER imbalance and the 
resulting intermediates can profoundly affect cellular and tissue homeostasis, and reveal 
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that in certain contexts, the absence of DNA repair can actually be beneficial to an 
organism.    
 
Although it has been known for 30 years that Parp inhibition potentiates alkylation-
induced toxicity [56], the recent discovery of synthetic lethality in BRCA1/2 homologous 
recombination-deficient tumors upon Parp inhibition has renewed intense interest in 
using PARP inhibitors for cancer chemotherapy [57,58].   However, in stark contrast to 
this well-documented potentiation of alkylation toxicity by Parp inhibitors [29,59], we 
observe complete suppression of alkylation toxicity by genetic deletion of Parp1.  This is 
likely due to multiple inherent differences between Parp1 deficiency and Parp inhibition 
[60].  The main difference is the proposed trapping of Parp1 on DNA substrates by Parp 
inhibitors, which thereby prevents BER and interferes with replication [61,62].  Although 
this ‘DNA trapping’ phenomenon has been demonstrated for many Parp inhibitors, it may 
not be the case for all Parp inhibitors [62,63,64,65].  In fact, uncovering the relationship 
between the inhibition of the catalytic activity of Parp, the potency of DNA trapping, and 
overall toxicity by Parp inhibitors has recently garnered interest [64].  Another difference 
between Parp1 deficiency and Parp inhibition resides in the fact that PARP inhibitors are 
not specific for the inhibition of Parp1, but can potentially inhibit the catalytic activity of 
17 other members of the Parp superfamily [66].  Regardless of the differences between 
Parp1 deletion and Parp inhibition, suppression of alkylation toxicity upon treatment of 
cultured cells with Parp inhibitors is not unprecedented [42,67,68,69].    
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Although Parp1 deficiency mechanistically differs from Parp inhibition, it was surprising 
to observe that Parp1 deficiency was capable of completely suppressing MMS 
hypersensitivity in numerous tissues under conditions of imbalanced BER (AagTg mice).  
This in vivo data reveals that Parp1 acts downstream of Aag to govern alkylation 
sensitivity, presumably through Parp1’s alternate function in mediating programmed 
necrosis (Figure 1B) [11,69].  Interestingly, interrupting Parp1’s function has been shown 
to be protective in several other models of neuronal damage including 
ischemia/reperfusion and glutamate excitotoxity [70,71,72], and retinal degeneration 
induced by ischemia/reperfusion or by treatment with PDE6 inhibitor, which mimics the 
rd1 mutation [73,74].  Whether Aag also plays a role upstream from Parp1 in these 
modes of tissue damage remains to be determined. 
 
Using genetic experiments, we show here that modestly increased Aag activity results in 
dramatic increases in tissue and whole-animal sensitivity to alkylating agents.  Given that 
human AAG activity varies greatly among healthy individuals (Figure 2), and also that 
BER protein levels are known to be altered in numerous human cancers [75,76,77], the 
resulting imbalanced BER may have dramatic consequences in patients undergoing 
chemotherapy involving alkylating agents [6].  Moreover, PARP1 expression and activity 
varies greatly in human tumors [78], and SNPs in PARP1 have been associated with 
numerous cancers [79,80,81].  We illustrate that Parp1 deficiency protects against 
alkylation sensitivity at both the tissue and whole-animal level.  Therefore, decreased 
PARP1 activity may result in a decreased response during a chemotherapeutic regimen.  
Indeed, leukemic patients expressing decreased PARP1 levels exhibit resistance to 
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standard chemotherapy therapy [82,83].  Taken together, our findings illustrate that 
monitoring for both BER imbalance and PARP1 expression is warranted prior to 
selecting a chemotherapeutic regimen that includes alkylating agents.  
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MATERIALS AND METHODS 
 
Ethics Statement 
The MIT Committee on the Use of Humans as Experimental Subjects reviewed and 
approved the research involving human subjects.  Written informed consent was obtained 
from all participants.  All animal procedures were approved by the MIT Committee on 
Animal Care. 
 
Animals 
Aag
-/-
 mice and Aag transgenic (AagTg) mice were described previously [20,28].  Parp 
-/- 
mice (Jackson Laboratories) are on a 129S6/SvEv background [50].  Mice were fed a 
standard diet ad libitum, housed in an AAALAC-accredited facility, and euthanized by 
CO2 asphyxiation.  Additional details about the mice utilized are included in the 
Supplemental Information.    
 
Reagents 
Methyl methanesulfonate (MMS), chloroacetaldehyde (CAA), N-methyl-N-nitrosurea 
(MNU), and Mitomycin C (MMC) were obtained from Sigma (St. Louis, MO).  
Azoxymethane (AOM) was obtained from the Midwest Research Institute, NCI Chemical 
Repository.    
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Treatments 
Whole-animal sensitivity to genotoxic agents was determined as in Deichmann and
 
LeBlanc [84].  Acute MMS treatments were performed by i.p. injecting mice with 
varying doses of MMS (60-150 mg/kg).   
 
Tissue Processing and Histopathology 
Tissues were processed at the David H. Koch Institute for Integrative Cancer Research, 
Histology Core Facility; they were paraffin-embedded, sectioned at 5 m, and stained 
with hematoxylin and eosin (H&E).  All H&E stained slides were blindly analyzed by a 
pathologist (R.T.B) for the cause of death as well as for the identification of any 
tumors/lesions.   
 
Image Quantitation 
Volocity (Perkin Elmer) image analysis software was used to quantitate edema, as 
observed by white spaces in cerebellar histological sections.  Thresholding was 
performed using the Red/Green/Blue quantitation tool and objects smaller than 5 microns 
were excluded.  The sum of all object areas/image was calculated and greater than 3 
representative images were analyzed for each of 3 animals.    
 
Ex vivo Bone Marrow Clonogenic Assays 
Bone marrow cells were harvested from the femurs of 6-12 weeks old WT, Aag
-/-
 and 
AagTg mice.  Cells were treated with varying dose of MMS, washed, resuspended in 
complete media mixed with methylcellulose (Stem Cell Technologies), plated in 
 24 
duplicate and the percent survival calculated as in [27].  Experiments were performed in 
triplicate. 
 
 Evaluation of Aag activity in mouse tissues  
Cell extracts were made from tissues harvested from WT, AagTg, and Aag
-/-
 mice.  
Tissues were sonicated in Aag glycosylase assay buffer (20 mM Tris-Cl pH7.6, 100 mM 
KCl, 5 mM EDTA, 1 mM EGTA and 5 mM -mercaptoethanol) with protease inhibitors.  
Protein concentration was measured using micro BCA Kit (Pierce).  Glycosylase assays 
were performed as previously published [20].  A [
32
P] labeled double-stranded 25mer 
oligonucleotide containing a single centrally located hypoxanthine residue 5'-
GCAATCTAGCTTTTT(Hx) CGATGTATGC-3' was incubated with an amount of 
extract that is in linear range for activity at 37C for 1h.  The resulting abasic sites were 
cleaved by incubation with 0.1 N NaOH at 70 C for 20 min. A phosphorimager was 
used to visualize and quantitate Aag DNA glycosylase activity.  Activity is expressed as 
fmols per µg of protein extracts.   
 
Evaluation of AAG activity in PBMC 
Peripheral blood samples were obtained from healthy individual at the MIT Catalyst 
Clinical Research Center, and PBMC were isolated using standard Ficoll-Paque
TM
 
(Sigma) density gradient centrifugations.  The in vitro glycosylase assay was performed 
as above with the following exceptions; the [
32
P]-labeled oligo-containing lesion used 
was 5'-GCAATCTAGCCA(A)GTCGATGTATGC-3', and the glycosylase reaction was 
incubated for 37C for 2h.      
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Evaluation of Motor Function 
To capture gait abnormalities, the mouse hind paws were dipped into non-toxic paint; 
mice were placed in a closed container on a sheet of white paper and allowed to walk 
freely.  The Ugo Basile 7650 Accelerating Rotarod (Varese, Italy) was used to evaluate 
fore-limb and hind-limb motor coordination.  The rotarod testing protocol was two weeks 
long; the first week examined motor function under untreated conditions and the second 
week following MMS-treatment.  An accelerating speed rotarod protocol was used, 
which linearly accelerates the rotating rod from 4 to 40 RPM in 10 minutes.  During each 
week, day 1 to 4 consisted of training the mice for two 5-minute runs to familiarize the 
mice with the apparatus.   On day 5, the mice underwent two tests, with an hour rest 
between the tests; the time spent on the rotatod is recorded as a measurement of 
performance.  The 2
nd
 week follows the same schedule, 4 days training and test on the 
fifth day.  However, on the 5
th
 day of the second week, the mice were treated with either 
60 or 140 mg/kg MMS by i.p. injection and the test performed 3 and 4-4.5 hours post-
treatment. 
 
Immunofluorescence 
Five 5m unstained sections were deparaffinized and rehydrated in a graded ethanol 
series, incubated in citrate buffer and thermally processed for epitope retrieval.  Sections 
were permeabilized with PBS-T (1x PBS + 0.1% Triton X-100; three times for 5 minutes 
each). Non-specific antibody binding sites were blocked by incubating sections with 1x 
PBS-T + heat-inactivated goat serum (HIGS; 10%) for 30 minutes. Sections were then 
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incubated with primary anti-PAR antibody (1:250; BD Pharmingen) for 2 hours at RT. 
After 5 washes in PBS-T, sections were incubated for 30 min with secondary antibody 
DyLight® 488 (1:1000; Vector Labs, USA). Counterstaining was done using TOPRO-3 
(Invitrogen). All staining was performed in humidified chambers.   A Zeiss Axiovert 
LSM 510 META confocal microscope (Germany) with a 63X oil objective was used to 
image the retinal sections.  Images were viewed and analyzed using LSM Image 
Browser. 
 
Statistics 
Statistical analyses were performed using GraphPad Prism software.  Data are 
represented as mean ± SEM.  Statistical significance was determined using unpaired t-test 
or two-way ANOVA.  Kaplan-Meier survival curves were generated and survival 
differences determined using the Log-Rank test.  A p-value is considered significant if 
less than 0.05. 
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FIGURE LEGENDS 
Figure 1. (A) The cellular processing of DNA base lesions by the base excision repair 
(BER) pathway.  DNA base lesions induced by SN1 or SN2 alkylating agent are 
recognized and excised by the DNA glycosylase, Aag, to generate an AP site.    BER 
continues when an AP endonuclease cleaves the DNA backbone to generate 3 hydroxyl 
and 5 deoxyribose phosphate (5dRP) termini.  Polymerase  removes the 5dRP species, 
and inserts the missing DNA bases; DNA ligase completes the BER by sealing the nicked 
DNA.  (B) Error-prone translesion (TLS) polymerases can assist in the tolerance or 
bypass of base lesions and AP sites.  Parp1 has an important role in regulating the 
response to DNA damage.  During times of moderate DNA damage, Parp1 activation 
facilitates BER.  Upon high levels of DNA damage, Parp1 undergoes hyperactivation; 
cells consequently suffer NAD
+
/ATP depletion, triggering cell death.    
 
Figure 2.  Human peripheral blood mononuclear cells (PBMCs) exhibit a wide range in 
AAG activity.  An in vitro glycosylase assay determined AAG activity in PBMCs 
isolated from 80 healthy individuals.   
 
Figure 3.  AagTg mice are more susceptible to MMS-induced toxicity. (A)  Body 
weight (BW) of WT (n=14), Aag
-/-
 (n=12) and AagTg (n=12) mice 24h following MMS 
treatment (75 mg/kg).  Representative data (mean ± standard deviation) from 3 
independent experiments are shown .  (B)  BW is illustrated for WT (n=14), Aag
-/-
 (n=12) 
and AagTg (n=9) mice following MMS treatment (75 mg/kg).  Data represent mean ± 
standard deviation.  (C)  Tissue weights of spleen and thymus are illustrated for n>6 per 
genotype.  Striped bars represent untreated tissue weights and solid bars represent tissue 
weights 24h following MMS treatment (75 mg/kg).  Percent decrease in tissue weight 
observed following MMS treatment is shown above bars. Data represent mean ± SEM.    
(D)  Ex vivo bone marrow (BM) clonogenic survival assays were performed using BM 
isolated from WT (n=3), Aag
-/-
 (n=3) and AagTg (n=3).  Data represent mean ±  
SEM.  All the mice used in this figure are males on a pure C57BL/6 background. 
 
Figure 4. MMS induces severe cerebellar lesions AagTg mice.  (A)  H&E stained 
image of cerebellar granule cells from WT, Aag
-/-
 and AagTg mice either in untreated 
conditions or 24h following MMS treatment (150 mg/kg).  Representative images are 
shown of n>6 experiments.  Yellow arrows indicate pyknotic nuclei.  Scale bar is 100m 
on low magnification images (black bar) and 15m on high-magnification images (white 
bar).  Insets contain magnified images of area in dashed boxes.    (B)  Quantitation of 
cerebellar phenotype was performed on images from WT (n=4), Aag
-/-
 (n=3) and AagTg 
mice (n=4).  Representative images with identified objects (edema) colorized for 
visualization.  Greater than 3 images/cerebella were quantitated per mouse, and the 
average sum of object area per image is presented. Data represent mean ± SEM.  All the 
mice in this figure are on a pure C57BL/6 background.
 
Figure 5.  MMS induces an Aag-dependent decrease in motor function.   (A)  
Representations of gait are shown for WT (n=3), Aag
-/-
 (n=3) and AagTg (n=3) mice 
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three hours following MMS treatment (90 mg/kg).  (B)  Rotarod performance is shown 
for WT (n=18), Aag
-/-
 (n=17) and AagTg (n=25) mice under untreated conditions and 
following MMS treatment (60 mg/kg).  Data represent mean ± SEM.  (C) Performance 
for the rotarod challenge is shown for WT (n=17) and Aag
-/-
 (n=22), 3 and 4h following 
MMS treatment (140 mg/kg).  Data represent mean ± SEM.  All the mice in this figure 
are on a pure C57BL/6 background. 
 
Figure 6.  Parp1 deficiency protects against Aag-dependent, MMS-induced toxicity 
in retina photoreceptors.  H&E stained retinal sections for WT, Aag
-/-
 , Parp1
-/-
 , 
AagTg, and AagTg/ Parp1
-/-
 under untreated conditions or 7d following MMS treatment 
(75 mg/kg).  Scale bar is 15m.  Representative images for n=5 mice/genotype are 
shown. All the mice used in this figure are mixed C57BL/6:129S background.  ONL, 
Outer nuclear layer; INL, inner nuclear layer. 
 
Figure 7.  Parp1 deficiency protects against Aag-dependent, MMS-induced motor 
dysfunction.  (A)  H&E stained cerebellar sections are shown from WT, Aag
-/-
 , Parp1
-/-
 , 
AagTg, and AagTg/ Parp1
-/-
 under untreated conditions or 24h following MMS treatment 
(150 mg/kg).  Scale bar is 15m.  Representative images for n=5 mice/genotype are 
shown.  (B)  Quantitation of cerebellar phenotype is shown.  Three or more 
images/cerebella were quantitated per mouse, and 3 mice per genotype analyzed for 
quantitation; the average sum of object area (edema) per image is presented.  (C)   
Performance during the rotarod challenge in WT (n=15), AagTg (n=18), and 
AagTg/Parp1
-/-
 (n=9) is illustrated under untreated conditions and following MMS 
treatment (60 mg/kg).  (D) Performance for the rotarod challenge is shown for WT (n=8), 
Aag
-/-
 (n=10), and Parp1
-/-
 (n=15) mice four hours following MMS treatment (140 
mg/kg).  All the mice used in this figure are mixed C57BL/6:129S background.  All data 
represent mean ± SEM. 
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Supplemental Figure 1.  (A)  Aag activity is illustrated for a panel of tissues in WT, Aag-
/- and AagTg mice.  In vitro glycosylase assays were performed on tissues isolated from 
n=3 animals.  (B)  Kaplan Meier Survival curves are shown for an aging cohort of WT 
(n=19), Aag-/- (n=27) and AagTg (n=26) mice.   
 
Supplemental Figure 2.  Aag transgene expression does not result in MMS atrophy in 
all tissues.  Tissue weights of the heart, left kidney, brain, left gonadal fat pad, and left 
gastrocnemius/soleus skeletal muscles were taken in untreated and 24hour post MMS 
treatment (75 mg/kg).  The mice utilized in this experiment were age-matched males on 
a pure C57Bl/6 background. 
 
Supplemental Figure 3.  MMS induces pancreatic beta-cell death AagTg mice.  H&E 
stained slides of pancreatic -islets (outlined in yellow) from WT, Aag-/- and AagTg mice 
either in untreated conditions or 24h following MMS treatment (150 mg/kg).  Untreated 
sections show healthy pancreatic histology.  Following MMS treatment, only AagTg 
exhibit evidence of toxicity within the beta-cells, as illustrated by pyknotic and 
fragmented nuclei (shown by yellow arrows); the pancreatic beta-islets are outlined in 
yellow.  Very few intact nuclei are observed in the pancreatic beta-islet of the MMS-
treated AagTg mice (green arrows).  Representative images are shown of n>3 
experiments.  Scale bar is 12 microns. 
 
Supplemental Figure 4.  Untreated mice exhibit similar gait.   Representations of gait 
are shown for WT (n=3), Aag-/- (n=3), and AagTg (n=3) mice prior to MMS treatment.     
 
Supplemental Figure 5.  Aag-dependent Parp1 activation is observed in the retinal 
outer nuclear layer following MMS treatment.  Immunofluorescence staining with -PAR 
antibody and TOPRO counterstain was performed on retinal sections from WT, Aag-/- 
and AagTg mice 24h following MMS (75 mg/kg) treatment.  ONL, outer nuclear layer; 
INL, inner nuclear layer. 
 
Supplemental Figure 6.  Parp1 deficiency protects against alkylation-induced 
pancreatic beta-cell death AagTg mice.  H&E stained slides of pancreatic -islets from 
WT, Aag-/-, Parp1-/-, AagTg, and AagTg/Parp1-/- mice either in untreated conditions or 
24h following MMS treatment (150 mg/kg).  Representative images are shown of n>2 
experiments.  The pancreatic beta-islets are centered in image and surrounded by 
pancreatic acinar cells.  Untreated sections show healthy pancreatic histology.  
Following MMS treatment, only AagTg exhibit evidence of pancreatic beta-cell toxicity, 
as illustrated by pyknotic and fragmented nuclei (yellow arrow).  Very few intact nuclei 
are observed in the pancreatic beta-islet of the MMS-treated AagTg mice (green 
arrows).  Magnification is 60X; scale bar is 16m.  
 
Supplemental Figure 7.  Parp1 deficiency protects against alkylation-induced gait 
abnormalities.  Representations of gait are shown for WT (n=3), Parp1-/- (n=2), AagTg 
(n=3) and AagTg/Parp1-/- (n=2) mice shown three hours following MMS treatment (90 
mg/kg).   
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Table 1. Approximate MMS LD50 for Aag transgenic mice 
Mouse Strain MMS LD50 
C57Bl/6 150 mg/kg 
Aag 
-/- 
150 mg/kg 
AagTg Fo 8756* 150 mg/kg 
AagTg Fo 943* 120 mg/kg 
AagTg Fo 243* 80 mg/kg 
* Indicates that the Aag transgene is expressed in an Aag
 -/-
 
background. 
 
 
 
 
 
Table 2.  Approximate LD50 of Aag 
-/-
 and Aag transgenic mice to various genotoxic agents 
  Approximate LD50  
Mouse Strain MMS MNU AOM MMC CAA 
C57Bl/6 150 mg/kg 118 mg/kg 28 mg/kg 9 mg/kg 15.2 mg/kg 
Aag 
-/-
 150 mg/kg 118 mg/kg 28 mg/kg 9 mg/kg 15.2 mg/kg 
AagTg Fo 243* 80 mg/kg 35 mg/kg 18 mg/kg 9 mg/kg 15.2 mg/kg 
MMS,  Methyl methanesulfonate; MNU,  N-methyl-N-nitrosourea; AOM , Azoxymethane;  
MMC, Mitomycin C; CAA, Chloroacetaldehyde. * Indicates that the Aag transgene is 
expressed in an Aag
 -/-
 background. 
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